Top Device Companies

Covidien Named Best Stock Choice To Buy In 2010 By Major Analyst

A major analyst expects Covidien’s to be the best stock choice next year, thanks to a slump-resistant and growing market for surgical instruments. The Citi Investment Research analyst cited Covidien’s business change in 2009 by selling three product lines—oxygen therapy, sleep diagnostics and radiopharmacies. At the same time, Covidien bought Aspect Medical Systems, Power Medical Interventions and VNUS Medical Technologies, all makers of products expected to drive Covidien to the top of the stock market, the analyst said. (Click here for more)

“Citi Analyst Names Covidien Top Pick For 2010” – BusinessWeek (12/22/09)

JUST PUBLISHED: Medical Device Market 2009: Interventional Cardiology - Find out who’s going beyond catheters and drug-eluting stents in this vibrant space with this 86-page Special Report previously published in IN VIVO: The Business & Medicine Report. Order yours now!

Covidien Completes $440 Million Acquisition Of VNUS Medical Tech

Covidien says it has completed all the parts of its buyout of VNUS Medical Technologies, a deal that cost $440 million. VNUS makes devices to treat various conditions in veins, and the deal gives Covidien a way to expand its own vascular business. VNUS products are to be absorbed as part of  Covidien’s line of products. (Click here for more)

“Covidien Completes VNUS Medical Buyout” – CNBC (AP) (6/17/09)

Get the week's top medical device news sent directly to you. Sign up for the FREE once-a-week email newsletter from Top Device Companies.com

 

Covidien Set to Compete in Vascular Business

Article preview from IN VIVO - May 2009

Covidien, following the acquisition of Vnus Medical Technologies and Bacchus Vascular, is establishing a global business unit focused on vascular surgery.

Medtech Investing 2009: What's Changed?

Article preview from Start-Up - May 2009

The medical device industry is undergoing a crisis of funding, but not of confidence, according to a panel of investors convened at Windhover's recent medtech conference, In3 West,. The conference panel sought to explore how the medical device investment community is operating in these troubled times, how they will invest going forward, and how they will support their companies if things don't improve. We were especially curious to know if the funding challenges that start-ups face are really due to the overall dire economy, or if that dark cloud merely masks changing fundamentals in the medical device industry that are making it more difficult for companies to find funding, gain FDA approval, and enjoy a healthy exit. Our panel weighs in on the matter.

Vnus Buy Latest Big Win for 2004 Device IPO Class

Article preview from Start-Up - May 2009

The medical device industry broke the IPO ice in 2004, sending 17 companies onto the US public markets. How have they fared?